Alvine Initiates Phase I Trial for Celiac Disease Treatment
Posted on: Thursday, 14 February 2008, 12:00 CST
Alvine Pharmaceuticals has said that the first study subject was dosed in a single-blind, placebo controlled, dose-escalation Phase I clinical trial of its lead clinical candidate ALV003, which is in development for the treatment of patients with celiac disease.
Approximately 36 subjects are planned for enrollment in the trial to be conducted in the US. Both healthy human volunteers and subjects with celiac disease are expected to be dosed in this trial.
Source: Datamonitor
Related Articles
- Murder Trial Begins in 'Windshield' Death
- Martha Stewart's Trial Set for Jan. 12
- Clinical Trial Results May Boost ImClone
- Ericsson Spy Trial Begins in Stockholm
- Design and quality control issues related to dietary assessment, randomized clinical trials and meta-analysis of field-based studies in developing countries1
- Paper: Thief on Trial for Courtroom Theft
- Clinical Trials Update: Mar. 11, 2003
- Clinical Trials Update: Mar. 5, 2003
- Dogs of Skiers Leaving Unhappy Trials
- Clinical Trials Update: Jan. 27, 2003
Rating: 3.5 / 5 (4 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds